Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome: a Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06681012

Title field or adapter rule

{'original_value': 'Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome: a Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:35.507931+00:00

Published At

2026-04-03T00:00:00+00:00

Record Updated At

2026-04-03

Source Retrieved At

2026-10-31T22:18:52.668840+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Irritable Bowel Syndrome (IBS)", "Irritable Bowel Syndrome of Diarrhea Type (IBS-D)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-04-03", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06681012"

protocolSection.identificationModule.officialTitle

"Gelsectan\u00ae in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome: a Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled Study"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["NA"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Irritable Bowel Syndrome (IBS) (protocolSection.conditionsModule.conditions)
• Irritable Bowel Syndrome of Diarrhea Type (IBS-D) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Gelsectan®'], 'description': 'Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).', 'name': 'Gelsectan®', 'type': 'DEVICE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Placebo'], 'description': 'Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).', 'name': 'Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Placebo (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.